CN101229220B - Compound for preventing and curing pseudomyopia and preparing method thereof - Google Patents
Compound for preventing and curing pseudomyopia and preparing method thereof Download PDFInfo
- Publication number
- CN101229220B CN101229220B CN 200810017289 CN200810017289A CN101229220B CN 101229220 B CN101229220 B CN 101229220B CN 200810017289 CN200810017289 CN 200810017289 CN 200810017289 A CN200810017289 A CN 200810017289A CN 101229220 B CN101229220 B CN 101229220B
- Authority
- CN
- China
- Prior art keywords
- composition
- percent
- pseudomyopia
- clear paste
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for preventing and treating pseudomyopia; the invention is prepared with the following materials by weight percentage: the gross weight of 100 percent; safflower of 40 percent to 50 percent, and semsemen astragali complanatien astragali complanati of 50 percent to 60 percent. The invention also discloses the preparation method of the composition, which is implemented by the following steps and a two-taste remedy is received according to the above proportions; 8 to 8.5 times of water is added for each decoction, the composition is decocted for two times, and 1.4 to 1.6 hours each time, and then the decocted liquid is combined and filtered; the filtrate is concentrated to a clear paste with a relative density of 1.24 to 1.26 and the composition is received. The composition of the invention has significant efficacy, the taking of the composition is convenient, the remedy is simple, and the medicine source is abundant; the composition of the invention is easy for preparation and has no toxic and side effect; the composition is a good medicine for treating pseudomyopia of adolescent and a prevention and health product.
Description
Technical field
The present invention relates to a kind of compositions, be specifically related to a kind of compositions be used to preventing and treating pseudomyopia, the invention still further relates to the preparation method of said composition.
Background technology
Along with the development of society, the adolescent student learning pressure is more and more heavier, makes continuous use excessively of a specified duration at the moment, looks bad the eye customs of using such as thing hypotelorism in addition, and near-sighted sickness rate is constantly raise.According to domestic document announcement, " middle school student's myopia sickness rate rises in recent years, and the class of graduating from the high school is up to 60～70%, and the junior middle school student is more than 40%, pupil nearly 20% ".
Treatment for myopia, doctor trained in Western medicine is mainly taked to adjust diopter (such as wearing glasses) and is improved vision, and with neurotrophy medicine etc., due to the restriction of conditions environmental, a lot of patients can not receive treatment as early as possible, the long-term toxic and side effects of the inconvenience that adding wears glasses brings and medicine, many people are unwilling to use, aggravate disease, and for the pseudomyopia at initial stage, the curative effect of doctor trained in Western medicine is not obvious.In the method for utilizing the Chinese medicine pseudomyopia, in the process of using the methods such as oral Chinese medicine, outer note, washout, eye dripping, acupuncture, massage, all make some progress, but its curative effect is all slower, be difficult to adhere to for a long time use for common people such as Chinese herbs decoction, outer lotions, and acupuncture is difficult for being accepted by School adolescents, all be difficult to promote the use of, therefore be badly in need of a kind ofly conveniently taking, compositions evident in efficacy is used for the treatment of teenage pseudomyopia.
Summary of the invention
The purpose of this invention is to provide a kind of compositions be used to preventing and treating pseudomyopia, solved Western medicine drug, method is not obvious for the pseudomyopia curative effect at initial stage, use the long-term toxic and side effects of the inconvenient and medicine of glasses; The tcm methods curative effect is slower, the problem that is difficult to promote the use of.
Another object of the present invention is to, the preparation method of foregoing is provided, guarantee drug effect, simplify production technology, reduce cost of manufacture, conveniently take.
The technical solution adopted in the present invention is, a kind of compositions be used to preventing and treating pseudomyopia, and made by following raw materials by weight: Flos Carthami 40%～50%, Semen Astragali Complanati 50%～60%, gross weight are 100%.
Another technical scheme of the present invention is, the preparation method of aforementioned compositions be used to preventing and treating pseudomyopia is implemented according to following steps,
Be 100% according to gross weight, the ratio of Flos Carthami 40%～50%, Semen Astragali Complanati 50%～60% takes above two flavor prescriptions; Each 8.0～8.5 times of amounts of water that add that decoct decoct secondary, and each 1.4～1.6 hours, collecting decoction filtered; It is 1.24～1.26 clear paste that filtrate is concentrated into relative density, and get final product.
The invention has the beneficial effects as follows, overcome Western medicine drug, method is not obvious for the pseudomyopia curative effect at initial stage, use glasses inconvenient; Tcm methods is difficult for promoting the use of, and curative effect is problem more slowly all.Can effectively treat teenage pseudomyopia, said composition is made simple, taking convenience, the health-care effect that have simultaneously the kidney invigorating, invigorate blood circulation, makes eye bright.
The specific embodiment
The present invention is described in detail below in conjunction with the specific embodiment.
Bathomorphic pathogeny, most scholars think it is mainly continuously excessively of a specified duration with eye, close to too, the not reciprocity bad eye hygiene custom of eye posture is too much regulated eye frequently depending on object distance, and shrink with the outer muscle tonus of binocular integration, local generation is congested, and metabolite is accumulated, and causes the ophthalmic ciliary spasm, eyesight weaken becomes myopia.The traditional Chinese medical science is thought bathomorphic pathogeny, is mainly deficiency of the liver and kindey, the QI and blood dysfunction, and due to the order network is retarded by silt, second certain herbaceous plants with big flowers homology, thus multiplex liver and kidney tonifying, promoting blood circulation to remove obstruction in the collateral, making eye bright is the primary treatment method.
One, Chinese medicine constituent of the present invention and percentage by weight are:
Wherein Flos Carthami 40%～50%, Semen Astragali Complanati 50%～60%, gross weight is 100%.
Two, the function of each medicine material of the present invention and function cure mainly
1, Semen Astragali Complanati is Weihe water special product, Qin's ground famous medicine, the sweet temperature of its property, nontoxic, have tonifying the kidney to consolidate the essence, nourishing the liver to improve visual acuity, the mind calming and mentality promoting moistens the function of fitness, can cure congenital defect, controls and lacks of proper care after one's birth, clothes can promote organism metabolism for a long time, health invigorating with to the two empty eyesight weakens of Liver and kidney, is had a dizzy spell especially, the neurasthenia, soreness of waist gonalgia has significant curative effect.Utilize its tonifying liver in we, kidney tonifying makes eye bright, and the effect of controlling nocturnal emission with astringent drugs is as principal agent, treating the liver kidney deficiency, soreness of waist and knee joint, the diseases such as blurred vision.
2, the hot tepor of Flos Carthami, cure mainly all cards of the blood stasis that stimulates the menstrual flow, and is product on the nourshing blood and promoting blood circulation collateral dredging.Utilize its promoting blood circulation to restore menstrual flow in we, the effect of blood stasis removing pain relieving is as accessory drugs, and excited expansion vim and vigour activate the effect of ciliary muscle, thereby remove spasm, improve blood circulation, recover vision.
As from the foregoing, the effect of Flos Carthami and Semen Astragali Complanati is different, complements each other, folk prescription to the treatment of myopia all from the effect of certain physical therapy and health care is arranged in essence, but when each folk prescription is specifically taken, the medicinal inconvenience of folk prescription, make numerous and diversely, generally other promotes the use of inconvenience.The pseudomyopia that the present invention is directed to, the morbidity course of disease must be empty with prolonged illness generally more than half a year, and prolonged illness must the stasis of blood, utilizes Semen Astragali Complanati tonifying the kidney to consolidate the essence nourishing the liver to improve visual acuity, uses the Flos Carthami promoting blood circulation to remove obstruction in the collateral.Compositions of the present invention is through a large amount of for many years experiments, more numerous folk prescription raw materials, choose Flos Carthami and Semen Astragali Complanati two flavor Chinese medicines, and their proportion compatibility has been carried out a large amount of contrast experiments, optimize the best formula percentage of drug effect, and adopt special preparation method, preserved the organic principle of Flos Carthami and Semen Astragali Complanati two flavor Chinese medicines, 5 one benefits one are alive mutually to adopt two medicines, bring out the best in each other, improved comprehensive drug, obtained significant therapeutic effect, the health-care effect that the kidney that gathers altogether makes eye bright.
(3), the function of compositions of the present invention cures mainly: be used for the treatment of teenage pseudomyopia, the effect that also have the kidney invigorating, invigorate blood circulation, makes eye bright.
Three, the preparation technology of compositions of the present invention and embodiment:
Be 100% according to gross weight, wherein the ratio of Flos Carthami 40%～50%, Semen Astragali Complanati 50%～60% takes above two flavor prescriptions; Each 8.0～8.5 times of amounts of water that add that decoct decoct secondary, and each 1.4～1.6 hours, collecting decoction filtered; It is 1.24～1.26 clear paste that filtrate is concentrated into relative density, and get final product.
Compositions of the present invention can be made into according to different consumer objects various finished products, is made into granule, tablet or capsule etc. such as being aided with Mel and sucrose.When being made into granule, aforesaid clear paste and sucrose need to be taken sucrose according to 1: 1.40～1.45 ratio, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Embodiment 1
Be 100% according to gross weight, Flos Carthami is 40%, Semen Astragali Complanati is that 60% ratio takes above two flavor prescriptions; Each 8.0 times of amounts of water that add that decoct decoct secondary, and each 1.4 hours, collecting decoction filtered; It is 1.26 clear paste that filtrate is concentrated into relative density, and get final product.
When being made into granule, aforesaid clear paste and sucrose are taken sucrose according to the ratio of 1: 1.40, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Embodiment 2
Be 100% according to gross weight, Flos Carthami is 50%, Semen Astragali Complanati is that 50% ratio takes above two flavor prescriptions; Each 8.2 times of amounts of water that add that decoct decoct secondary, and each 1.5 hours, collecting decoction filtered; It is 1.24 clear paste that filtrate is concentrated into relative density, and get final product.
When being made into granule, aforesaid clear paste and sucrose are taken sucrose according to the ratio of 1: 1.43, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Embodiment 3
Be 100% according to gross weight, Flos Carthami is 45%, Semen Astragali Complanati is that 55% ratio takes above two flavor prescriptions; Each 8.0 times of amounts of water that add that decoct decoct secondary, and each 1.5 hours, collecting decoction filtered; It is 1.25 clear paste that filtrate is concentrated into relative density, and get final product.
When being made into granule, aforesaid clear paste and sucrose are taken sucrose according to the ratio of 1: 1.45, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Embodiment 4
Be 100% according to gross weight, Flos Carthami is 43%, Semen Astragali Complanati is that 57% ratio takes above two flavor prescriptions; Each 8.5 times of amounts of water that add that decoct decoct secondary, and each 1.6 hours, collecting decoction filtered; It is 1.25 clear paste that filtrate is concentrated into relative density, and get final product.
When being made into granule, aforesaid clear paste and sucrose are taken sucrose according to the ratio of 1: 1.42, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Four, toxicity test
Select 120 of healthy SD rat, body weight 50～60g, male and female half and half.The plan quantity of medicine is that boiled water is taken after mixing it with water 5～10g/ time, and 2 times/days, the 10g electuary is equivalent to crude drug 11g, and 1g extractum is equivalent to crude drug 6.5g; Intending clinical research on maximum utilized quantity is 0.37g/ kilogram/day (people's body weight is in 60 kilograms).The long poison of rat gives with Cmax 50% gavage, and dosage is designed to 44g/kg, 22g/kg, 11g/kg (be equivalent to intend quantity 120 times, 60 times, 30 times).According to the specification requirement of long term toxicity test, test period is defined as 3 months.Therefore 6 months long term toxicity tests (the administration result of the test of 3 months has been chosen in this test) of rat have been carried out.
Experimental apparatus is used the 7170A type automatic clinical chemistry analyzer of Japan, and hematological indices is used the CD-1600 of Abbott Laboratories instrument.
Experiment raising condition: laboratory temperature is 18～24 ℃, and relative humidity is 58%～62%, the air-conditioning homoiothermic, and natural lighting, exhaust fan ventilates, and sweeps the Mus house once in every three days.The food solid feed is freely drunk water.
Experimental technique: get 120 rats, observe one weeks of situation such as animal activity, feed, feces before administration, all find without abnormal, be divided at random four groups by body weight, 30 every group, divide the cage group support by sex, 5, every cage, matched group water, small dose group 11g/kg, middle dosage group 22g/kg, heavy dose of group 44g/kg are set, and the administration group is by above-mentioned dosage gavage, and matched group is given isopyknic water.Every day gavage once.the animal drinking-water of freely ingesting, weigh weekly once, adjust dosage according to body weight, and observation animal activity, fur, the feces situation, after administration 3 months, put to death 10 rats for every group, male and female half and half, blood sampling checks the hematology, blood biochemical is learned index, and sacrificed by exsanguination rat solution digs each important organ, after one's own heart, liver, spleen, lung, kidney, brain, the adrenal gland, thymus, testis, the seminal vesicle prostate, ovary, the uterus, claim weight in wet base, body weight during according to execution is calculated organ coefficient, get following internal organs and carry out pathologic finding: the heart, liver, spleen, lung, kidney, brain, hypophysis cerebri, optic nerve, eyeball, stomach, duodenum, ileum, colon, the breast bone, the adrenal gland, thymus, thyroid, bladder, testis, the seminal vesicle prostate, ovary, the uterus.Survey weekly appetite one time.After administration 6 months, put to death again 10 rats, male and female half and half for every group, repeat above-mentioned detection, drug withdrawal recovered one month, and all the other rats are repeated above-mentioned detection, each organizes experimental data all with expression, carries out t check (data comprise the administration experimental result of 3 months) between group.
Experimental result: to the observation of rat general status: administration group and control rats are all movable normal in 3 months experimental sessions, and behavior is active, and hair is smooth, has no feces abnormal, without pathological changes such as secretions and dyspnea, and none death.Impact on rat body weight: each organizes there was no significant difference.
Impact and conclusion on the Rats Organs and Tissues coefficient: the heart, liver, spleen, lung, kidney, brain, adrenal gland, thymus, testis, seminal vesicle prostate, ovary, uterus, the organ coefficient statistics compares with the water matched group, unknown significance difference.See the following form 1, unit is (x, g%), with matched group ratio, P＞0.05.
Table 1 is the experimental data on the impact of rat important organ index:
Continued 1
Long-term gastric infusion sees the following form 2 and continued 2 to hematological impact, and unit is
Table 2 is long-term gastric infusion on the experimental data of hematological impact:
Continued 2
The impact of long-term gastric infusion on the rat blood biochemical indexes sees Table 3 and continued 3
Table 3 table 3 is long-term gastric infusion on the impact of rat blood biochemical indexes:
Continued 3
Continued 3
Conclusion: on the impact of rat appetite, the animal of three dosage groups and matched group increases basically identical,
Have no significant effect.On the impact that rat blood is learned, Non Apparent Abnormality.On the impact of rat blood biochemical indexes, Non Apparent Abnormality.
Inspection to the rat histopathology: the heart, liver, spleen, lung, kidney, brain, hypophysis cerebri, optic nerve, eyeball, Stomach duodenum, ileum, colon, breastbone, adrenal gland, thymus, thyroid, bladder, testis, seminal vesicle prostate, ovary, each internal organs outward appearance of uterus of three dosage groups and matched group are normal, pathology solution plane is learned and histopathologic examination, and each internal organs are showed no the obviously abnormal pathological change relevant to being subjected to reagent.This experiment contrast group has an example hepatic cell fattydegeneration performance to occur, and is irrelevant with administration; Interstitial pneumonia is many to be caused by viral infection, and matched group and heavy dose of group all have distribution, research thinks and administration irrelevant, so this experiment to lungs also without the coup injury effect.
The above results shows, compositions of the present invention all has no significant effect ordinary circumstance, body weight, diet drinking-water, hematology, blood biochemical, system's dissection, organ coefficient and the histopathology of rat, do not find the long term toxicity reaction, convalescent period, prompting: the nontoxic amounts of reactants of rat was 44g/kg/ day also without the retardance toxic reaction.
Five, clinical observation
1, clinical case: male's 47 examples, women's 53 examples.Minimal ages 7 years old, maximum 24 years old age, average 15 years old.The course of disease wherein: person's 7 examples more than 10 years, person's 23 examples more than 5 years, person's 22 examples more than 3 years, person's 29 examples more than 1 year, not quite clear person's 19 examples of time.
Symptom and sign: this organizes 100 routine patients, 184 of sick eyes, vision is 13 of passerbys, and vision is 30 of two passerbys, and vision is 31 of three passerbys, vision is 25 of four passerbys, vision is 24 of five passerbys, and vision is 24 of six passerbys, and vision is 23 of seven passerbys, vision is 12 of eight passerbys, and vision is 2 of nine passerbys.Conscious headache person's 2 examples, blurred vision person 38 examples, dry and astringent person's 11 examples of eyes, ophthalmalgia person 2 examples.
Therapeutic Method: we are made into dissolved granule, every bag 12g.Oral, every day 2 times, each 6～12g, warm boiled water.Take medicine and the method for the other treatment myopia of stopping using during this medicine, 15 days is a course for the treatment of, and 85 example groups take three courses for the treatment of altogether, and 15 example groups take two courses for the treatment of altogether.
Table 4 is vision distribution situation before and after treatment
Continued 4
Table 5 improves distribution situation for the rear vision for the treatment of
Table 6 is the rear glucose recovery situation for the treatment of
Therapeutic outcome: efficacy determination, vision reach 1.0 or above person for the recovery from illness; Vision increases by 3 rows or above person is produce effects; Vision increases by 1～2 row person for taking a turn for the better; Vision does not increase to invalid.
Therefore, in 184 routine clinical case treatments, 48 (26.1%) for the treatment of recovery from illness, 46 of produce effects (25%) take a turn for the better 80 (48.5%), invalid 10 (5.4%).184 routine clinical cases mean vision after treatment improves 2.698 ± 1.623, illustrates that compositions of the present invention has significant curative effect.
2,15 normal healthy peoples are being carried out the I clinical trial phase.
Clinical case: male's 8 examples, women's 7 examples.Minimal ages 19 years old at maximum 24 years old age, average 21 years old, is the student enrollment.
Experimental technique: after all carrying out the inspection of electrocardiogram, liver function, renal function, routine blood test, urine, stool routine, select above-mentioned 15 healthy persons.We are made into dissolved granule, every bag 12g.Oral, every day 2 times, each 12g, warm boiled water.Took continuously 30 days.Carry out again the inspection of same electrocardiogram, liver function, renal function, routine blood test, urine, stool routine.
Table 7 is each functional check situation before and after taking medicine:
| Electrocardiogram | Liver function | Renal function | Routine blood test | Routine urinalysis | Stool routine | ||
| The front number of cases of the taking medicine rear number of cases of taking medicine | The normal normal number anomalous number of number anomalous number | 150150 | 150150 | 150150 | 150150 | 150150 | 150150 |
Table 8 is the liver function situation:
The new concentration icteric index of thymol concentration sulphuric acid
n 15 15 15
n′ 14 14 14
x 0.3333 0.06667 0.1333
s 0.7888 1.48174 0.8055
sx 0.20367 0.3826 0.20799
t 1.6365 0.1747 0.6409
P value＞0.05＞0.05＞0.05
Table 9 is renal function statistical procedures situation:
| n | N ' | x | s | Sx | t | The P value | |
| Nitrogen CO2CP | 15 15 | 14 14 | 0.1533 0.2333 | 2.6048 7.5363 | 0.6726 1.9458 | 0.2279 0.1199 | >0.05>0.05 |
Table 10 is routine blood test statistical procedures situation:
| n | N ' | x | s | Sx | t | The P value | |
| Red blood cell leucocyte hemochrome | 15 15 15 | 14 14 14 | 31.47 12 0.3867 | 94.102 1.544 0.9542 | 24.296 389.66 0.2464 | 1.2979 0.0301 1.5694 | >0.05>0.05>0.05 |
Experimental result: except above-mentioned table 7,8,9,10, also have turn peace enzyme, VDB, iodine test in electrocardiogram, urine, stool routine and liver function all to represent with normal and feminine gender, all results of comparison are all in normal range.
In sum, compositions of the present invention thinks that by clinical observation prescription is simple, and the medicine source is abundant, be easy to preparation, easy to use, clinical efficacy is better, through normal human's test and toxicological test, to the heart, liver, kidney all without any infringement, have curative effect better, inexpensive convenience, the advantage such as have no side effect, can recover to improve vision, be a kind of good medicine and prevention and health care articles for use for the treatment of teenage pseudomyopia.
Claims (1)
1. the preparation method for the compositions of preventing and treating pseudomyopia, is characterized in that, implements according to following steps:
Be 100% according to gross weight, Flos Carthami is 45%, Semen Astragali Complanati is that 55% ratio takes above two flavor prescriptions; Each 8.0 times of amounts of water that add that decoct decoct secondary, and each 1.5 hours, collecting decoction filtered; It is 1.25 clear paste that filtrate is concentrated into relative density, and get final product,
Aforesaid clear paste and sucrose are taken sucrose according to the ratio of 1: 1.45, take in addition appropriate dextrin, with clear paste, sucrose, dextrin three mix homogeneously, granulation and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810017289 CN101229220B (en) | 2008-01-15 | 2008-01-15 | Compound for preventing and curing pseudomyopia and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810017289 CN101229220B (en) | 2008-01-15 | 2008-01-15 | Compound for preventing and curing pseudomyopia and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229220A CN101229220A (en) | 2008-07-30 |
| CN101229220B true CN101229220B (en) | 2013-06-12 |
Family
ID=39896234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810017289 Active CN101229220B (en) | 2008-01-15 | 2008-01-15 | Compound for preventing and curing pseudomyopia and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229220B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523799A (en) * | 2015-01-31 | 2015-04-22 | 高君琳 | Externally-applied traditional Chinese medicine liquid for preventing myopia and treating early pseudomyopia and preparation method thereof |
| CN105012542A (en) * | 2015-08-04 | 2015-11-04 | 庞英杰 | Traditional Chinese medicine eye mask for treating myopia |
-
2008
- 2008-01-15 CN CN 200810017289 patent/CN101229220B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 郝守真.小儿近视食疗方.药物与人 1.1994,(1),15. |
| 郝守真.小儿近视食疗方.药物与人 1.1994,(1),15. * |
| 陶根鱼，等.中药近视灵冲剂治疗青少年假性近视疗效观察.陕西中医学院学报13 2.1990,13(2),46-49. |
| 陶根鱼,等.中药近视灵冲剂治疗青少年假性近视疗效观察.陕西中医学院学报13 2.1990,13(2),46-49. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101229220A (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101810833B (en) | Chinese medicinal composition for treating edema and preparation method thereof | |
| CN102526327B (en) | Compound Chinese herbal medicine for treating rheumatoid bone disease and preparation method for compound Chinese herbal medicine | |
| CN102178911A (en) | Chinese medicine preparation used for dispelling wind and eliminating dampness, dredging collaterals and stopping pains for people with deficiency of yang and phlegm dampness constitution, and preparation method and application of preparation | |
| CN101884715B (en) | Medicament for treating optic neuritis and preparation method thereof | |
| CN101229220B (en) | Compound for preventing and curing pseudomyopia and preparing method thereof | |
| CN104274754A (en) | Traditional Chinese medicine composition for treating infantile enuresis and preparation method of traditional Chinese medicine composition | |
| CN101317873B (en) | Hyperosteogeny ache-reliving plaster and preparation method thereof | |
| CN101647913B (en) | Traditional Chinese medicine preparation for treating senile cataract and viral keratitis | |
| CN102743734A (en) | Application of Tianlou Guizhi decoction in treatment of post-stroke spasm | |
| CN104524464A (en) | Traditional Chinese medicine preparation for treating hyperactivity and preparation method of traditional Chinese medicine preparation | |
| CN100382837C (en) | A medicine for treating children's excessive blink, hyperkinetic syndrome and Tottre's syndrome and method for preparing same | |
| CN106177130A (en) | A kind of manufacture method of the Chinese medicine eye ointment treating myopia | |
| CN102813757B (en) | Preparation method of traditional Chinese medicine for treating lumbago type acute glomerulonephritis | |
| CN100998744A (en) | Chinese patent drug for treating infantile hyperkinetic syndrome | |
| CN104189038A (en) | Traditional Chinese medicine preparation for regulating female physical health and immunity | |
| CN101244181B (en) | Plaster for bone paralysis with function of qufengshengshi, blood circulation activating and stasis removing, and removing the obstruction in the channels to relieve pain, and preparation thereof | |
| CN110507796A (en) | A kind of Chinese medicine preparation for treating a variety of diseases | |
| CN109793866A (en) | A kind of Chinese medicine that treating prostatic diseases and preparation method | |
| CN103816426B (en) | A kind of pathogenic wind toxic for the treatment of enters the Chinese medicine of interior syndrome's type Tetanus | |
| CN102302702B (en) | Medicament for treating infantile diarrhea | |
| CN101862368B (en) | Medicament for treating leucoderma | |
| CN101797371A (en) | Drug combination for weight-reducing massage | |
| CN105194635A (en) | Traditional Chinese medicine composition for navel therapy for treating child diarrhoea and preparation method of traditional Chinese medicine composition | |
| CN105902600A (en) | Yaotongling wine and preparation method thereof | |
| CN116077574A (en) | Medicine for treating rheumatism bone diseases and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 710018, Mingguang Road, Xi'an, Shaanxi, 41 Patentee after: XI'AN E FANGGONG PHARMACEUTICAL CO., LTD. Address before: 710016 No. 41 Mingguang Road, Xi'an economic and Technological Development Zone, Shaanxi, Xi'an Patentee before: Xi'an Efanggong Pharmaceutical Co., Ltd. |